VIR/GILD addendum—I suspect the long delay in starting the phase-2 trial was procedural (i.e. not a lack of interest by the sponsors). Specifically, it may have taken some time to get the FDA’s buy-in on combining the four agents being tested in the trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”